Neoadjuvant Trastuzumab Plus Chemo in Primary Breast CancerNeoadjuvant Trastuzumab Plus Chemo in Primary Breast Cancer
Does the pathological complete response rate to trastuzumab in HER2-positive breast cancer depend on the level of HER2 mRNA expression? Breast Cancer Research
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Health | Hematology | HER2 | Herceptin | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy